|
|
 |
|
Viewing report
|
|
|
|
Prospects for the Phase III Bapineuzumab Trial
FirstLine Consulting Group, Sep 2009, Pages: 37
One of the most watched clinical trials is the phase III trial for bapineuzumab, a humanized monoclonal antibody designed to bind to and remove Aß in the blood and in the brain. Concerns have arisen over bapineuzumab phase II data presented last year in which extensive subanalysis was performed indicating strong efficacy in some subgroups. However, the subanalysis is viewed by some to be misleading. To understand the value of the phase II trial and the potential for success for the phase III trial, we performed a comprehensive analysis on the major issues of the trial. In our analysis, we have:
- Researched bapineuzumab phase I and phase II results in depth, and collected vast amounts of information that have helped us assess the true risk to safety and efficacy of the phase III trial.
- Consulted with many clinicians, as well as thoroughly researched comparative phase II and III trials to gain perspective on the results obtained with bapineuzumab so far.
- Carefully analyzed the perceived higher decline of ADAS-cog scores in the placebo arm and found surprising results.
- Investigated the apparent lack of dose response in the phase II trial and compared this to other biologic therapies.
- Assessed the safety issues of the phase III trial and how they may affect ultimate usage.
Our research produces unexpected conclusions about the potential for efficacy and risks of the phase III bapineuzumab trials. The research provided will help investors and companies alike to strategize efforts and investment in the Alzheimer’s disease market
Customers who bought this item also bought
Alzheimer's Disease Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011
Alzheimer Disease - New Drugs, Markets and Companies
Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
Pharmaceutical Partnership Deal Terminations
Advances in Alzheimer’s Disease Drug Discovery
Advances in the Design and Regulation of Adaptive Clinical Trials
Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
Pipeline and Commercial Insight: Alzheimer's Disease - Market cautiously awaits the first generation of disease-modifying therapies
Global Biopharma Outlook 2012 - Major US and EU Pharma
Product Profiles: Alzheimer's Disease - Immunotherapies can revolutionize treatment paradigm
|
|
|
|
